Zynex Inc (ZYXIQ)

Currency in USD
0.12
+0.05(+73.53%)
Closed·
ZYXIQ is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
0.070.12
52 wk Range
0.068.45
Key Statistics
Prev. Close
0.07
Open
0.07
Day's Range
0.07-0.12
52 wk Range
0.06-8.45
Volume
1.83M
Average Volume (3m)
5.91M
1-Year Change
-98.54%
Book Value / Share
-1.37
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ZYXIQ Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
3.70
Upside
+2,983.33%
Members' Sentiments
Bearish
Bullish
ProTips
RSI suggests the stock is in oversold territory

Zynex Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Buy
Moving Averages
Sell

Zynex Inc Company Profile

Zynex, Inc., together with its subsidiaries, designs, manufactures, and markets medical devices to treat chronic and acute pain, and activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company offers NexWave, a dual channel, multi-modality interferential current, transcutaneous electrical nerve stimulation, and neuromuscular electrical stimulation (NMES) device that is marketed to physicians and therapists by field sales representatives; NeuroMove, an electromyography and electric stimulation technology device; InWave, an electrical stimulation product for the treatment of female urinary incontinence; E-Wave, an NMES device; and M-Wave, an NMES device. It also supplies private labeled products, including electrodes for the delivery of electrical current to the body; and batteries for use in electrotherapy products. In addition, the company distributes Comfortrac/Saunders for cervical traction, JetStream for hot/cold therapy, LSO Back Braces for lumbar support, braces for rehabilitation support for knee and wrist, and Dynacomp for cold compression therapy. Further, it develops Zynex Fluid Monitoring System (CM-1500); Zynex Wireless Fluid Monitoring System (CM-1600), a noninvasive monitoring device designed to measure relative changes in fluid volume in adult patients; NiCO CO-Oximeter, a laser photoplethysmographic patient monitoring device; and HemeOx tHb Oximeter, a laser-based total hemoglobin pulse oximeter. The company provides its products for use in pain management and control; stroke and spinal cord injury rehabilitation; and fluid monitoring and pulse oximetry monitoring. It sells its products through direct sales force primarily in the United States. Zynex, Inc. was founded in 1996 and is headquartered in Englewood, Colorado. On December 15, 2025, Zynex, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of Texas.

Zynex Inc SWOT Analysis


Market Dynamics
Explore Zynex's position in the $900 million pain management market and its expansion into the $3.7 billion patient monitoring secto
Financial Crossroads
Delve into Zynex's recent financial performance, including revenue growth and earnings challenges, and its impact on future projections
Strategic Shifts
Uncover Zynex's product diversification strategy and sales force optimization efforts aimed at long-term growth and improved efficiency
Analyst Outlook
Discover varied analyst perspectives, with price targets ranging from $12 to $16, reflecting both optimism and caution about Zynex's future prospects
Read full SWOT analysis

Zynex Inc Earnings Call Summary for Q3/2025

  • Zynex Q3 2025 reported a $1.42 EPS loss (735% below forecast) and revenue of $13.36M (41% below forecast), causing stock to plummet 20.57% to $0.48
  • Revenue declined 73% year-over-year to $13.4M from $50M, attributed to TRICARE payment suspension and payer claim submission changes
  • Company faces significant debt challenges with $60M in convertible senior notes maturing in May 2026; cash on hand stands at $13.3M
  • Management has engaged Province LLC to explore strategic alternatives, capital-raising, and restructuring opportunities amid financial difficulties
  • New leadership is focusing on compliance initiatives and operational improvements while working with government agencies to address regulatory concerns
Last Updated: 2025-11-18, 10:12 a/m
Read Full Transcript

Compare ZYXIQ to Peers and Sector

Metrics to compare
ZYXIQ
Peers
Sector
Relationship
P/E Ratio
0.0x−1.0x−0.6x
PEG Ratio
0.00−0.010.00
Price/Book
−0.1x1.0x2.6x
Price / LTM Sales
0.0x4.0x3.2x
Upside (Analyst Target)
-77.0%42.7%
Fair Value Upside
Unlock28.6%6.4%Unlock

Analyst Ratings

1 Buy
0 Hold
0 Sell
Ratings:
1 analysts
Overall Consensus
Strong Buy

Analysts 12-Month Price Target:

Average 3.70
(+2,983.33% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Ladenburg Thalmann
Buy3.70+2,983.33%7.00UpgradeAug 01, 2025
RBC Capital
Hold2.00+1,566.67%3.00MaintainAug 01, 2025
H.C. Wainwright
Hold---DowngradeAug 01, 2025
RBC Capital
Hold3.00+2,400.00%4.00MaintainJul 15, 2025
H.C. Wainwright
Buy8.00+6,566.67%-MaintainJul 01, 2025

Earnings

Latest Release
Nov 17, 2025
EPS / Forecast
-1.42 / -0.17
Revenue / Forecast
13.36M / 22.71M
EPS Revisions
Last 90 days

ZYXIQ Income Statement

People Also Watch

2.490
BEAT
+2.05%
0.083
OCG
-3.49%
0.7840
KITT
-12.89%
25.64
OLMA
-2.25%

FAQ

What Is the Zynex (ZYXIQ) Stock Price Today?

The Zynex stock price today is 0.12

What Stock Exchange Does Zynex Trade On?

Zynex is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Zynex?

The stock symbol for Zynex is "ZYXIQ."

What Is the Zynex Market Cap?

As of today, Zynex market cap is 3.04M.

What Is Zynex's Earnings Per Share (TTM)?

The Zynex EPS (TTM) is -2.39.

When Is the Next Zynex Earnings Date?

Zynex will release its next earnings report on Feb 26, 2026.

From a Technical Analysis Perspective, Is ZYXIQ a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Zynex Stock Split?

Zynex has split 1 times.

How Many Employees Does Zynex Have?

Zynex has 1000 employees.

What is the current trading status of Zynex (ZYXIQ)?

As of Dec 30, 2025, Zynex (ZYXIQ) is trading at a price of 0.12, with a previous close of 0.07. The stock has fluctuated within a day range of 0.07 to 0.12, while its 52-week range spans from 0.06 to 8.45.

What Is Zynex (ZYXIQ) Price Target According to Analysts?

The average 12-month price target for Zynex is USD3.7, with a high estimate of USD3.7 and a low estimate of USD3.7. 1 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +2,983.33% Upside potential.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.